Minocycline protects dopaminergic neurons against long-term rotenone toxicity

Canadian Journal of Neurological Sciences

Volumn 37, Issue 1, 2010, Pages 81-85

  Radad, Khaled ^a   Moldzio, Rudolf ^b   Rausch, Wolf Dieter ^b  

^a Assiut University   (Egypt)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; MINOCYCLINE; PARAFORMALDEHYDE; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 76649136478     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009690     Document Type: Article

References (27)

1. Andressoo JO, Saarma M. Signalling mechanisms underlying development and maintenance of dopamine neurons. Curr Opin Neurobiol. 2008;18(3):297-306
2. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991;50(6):743-755
3. Dhillon AS, Tarbutton GL, Levin JL, Lowry LK, Nalbone JT, Shepherd S. Pesticide/environmental exposures and Parkinson's disease in East Texas. J Agromedicine. 2008;13(13):37-48.
4. Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology. 2009;72(17):65-73.
5. Schapira AH. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord. 2008;23(3): 515-520
6. Schapira AH. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology. 2009;72 (17):44-50.
7. Yrjänheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci. 1999;96(23): 13496-13500
8. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417(8684):74-78
9. Wang X, Zhu S, Drozda M, ZhangW, Stavrovskaya IG, Cattaneo E, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci. 2003;100(18):10483-10487
10. Quintero EM, Willis L, Singleton R, Harris N, Huang P, Bhat N, et al. Behavioral and morphological effects of minocycline in the 6- hydroxydopamine rat model of Parkinson's disease. Brain Res. 2006;1093(1):198-207.
11. Ryan ME, Ashley RA. How do tetracyclines work? Adv Dent Res. 1998;12(2):149-151
12. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci. 2001; 98(25):14669-14674
13. Gieseler A, SchultzeAT, Kupsch K, Haroon MF,Wolf G, Siemen D, et al. Inhibitory modulation of the mitochondrial permeability transtion by minocycline. Biochem Pharmacol. 2009;77(5): 888-896
14. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3(12): 1301-1306
15. Radad K, Moldzio R, Taha M, Rausch WD. Thymoquinone protects dopaminergic neurons against MPP(+) and rotenone. Phytother Res. 2009;23(5):696-700.
16. Gwag, BJ, Lobner D, Koh JY, Wie MB, Choi DW. Blockade of glutamate receptors unmasks neuronal apoptosis after oxygenglucose deprivation in vitro. Neuroscience. 1995;68(3):615-619
17. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168-179
18. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson's disease. Curr Pharm. 2004;10(6):679-686
19. Zhao F, Cai T, Liu M, Zheng G, LuoW, Chen J. Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. Toxicol Sci. 2009;107(1):156-164
20. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 2009;23(3):739-750
21. Pattison LR, Kotter MR, Fraga D, Bonelli RM. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J Neurol. 2006;253(9):1137-1142
22. Büeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol. 2009;218(2): 235-246
23. Fernandez-Gomez FJ, Gomez-Lazaro M, Pastor D, Calvo S, Aguirre N, Galindo MF, et al. Minocycline fails to protect cerebellar granular cell cultures against malonate-induced cell death. Neurobiol Dis. 2005;20(2):384-391
24. Domico LM, Cooper KR, Bernard LP, Zeevalk GD. Reactive oxygen species generation by the ethylene-bis-dithiocarbamate (EBDC) fungicide maneb and its contribution to neuronal toxicity in mesencephalic cells. Neurotoxicology. 2007;28(6): 1079-1091
25. Ahmadi FA, Linseman DA, Grammatopoulos TN, Jones SM, Bouchard RJ, Freed CR, et al. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J Neurochem. 2003;87(4):914-921
26. Moon Y, Lee KH, Park JH, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem. 2005;93(5):1199-1208
27. Filipovic R, Zecevic N. Neuroprotective role of minocycline in cocultures of human fetal neurons and microglia. Exp Neurol. 2008;211(1):41-51.